New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Go back to New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study| AbbVie (NYSE: ABBV) | Delayed: 248.78 -7.68 (2.99%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $251.84 | 52 Week Low | $50.71 | |||
| Day High | $254.62 | P/E | 53.97 | |||
| Day Low | $248.41 | EPS | $4.61 | |||
| Volume | 5,572,036 | |||||
